Farida Lamkarkach1, Eva Ougier2, Robert Garnier3, Claude Viau4, Marike Kolossa-Gehring5, Rosa Lange5, Petra Apel5. 1. ANSES, 14 rue Pierre et Marie Curie, 94701 Maisons-Alfort Cedex, France. Electronic address: farida.lamkarkach@anses.fr. 2. ANSES, 14 rue Pierre et Marie Curie, 94701 Maisons-Alfort Cedex, France. 3. Paris Poison Centre, Toxicology Department (FeTox), APHP, Lariboisière-Fernand-Widal Hospital, Paris, France. 4. Department of Environmental and Occupational Health, School of Public Health, University of Montreal, Canada. 5. German Environment Agency (UBA), Corrensplatz 1, 14195 Berlin, Germany.
Abstract
AIMS: The methodology agreed within the framework of the HBM4EU project is used in this work to derive HBM-GVs for the general population (HBM-GVGenPop) and for workers (HBM-GVWorker) exposed to cadmium (Cd) and its compounds. METHODS: For Cd, a significant number of epidemiological studies with dose-response relationships are available, in particular for kidney effects. These effects are described in terms of a relation between urinary Cd (U-Cd) or blood Cd (B-Cd) levels and low molecular weight proteinuria (LMWP) markers like beta-2-microglobulin (β2M) and retinol-binding protein (RBP). In order to derive HBM-GVs for the general population and workers, an assessment of data from evaluations conducted by national or international organisations was undertaken. In this work, it appeared relevant to select renal effects as the critical effect for the both groups, however, differences between general population (including sensitive people) and workers (considered as an homogenous population of adults who should not be exposed to Cd if they suffer from renal diseases) required the selection of different key studies (i.e. conducted in general population for HBM-GVGenPop and at workplace for HBM-GVWorker). RESULTS AND CONCLUSIONS: For U-Cd, a HBM-GVGenPop of 1 µg/g creatinine (creat) is recommended for adults older than 50 years, based on a robust meta-analysis performed by EFSA (EFSA, 2009a). To take into account the accumulation of Cd in the human body throughout life, threshold or 'alert' values according to age were estimated for U-Cd. At workplace, a HBM-GVWorker of 2 μg/g creat is derived from the study of Chaumont et al., (2011) for U-Cd, and in addition to this recommendation a HBM-GVworker for B-Cd of 5 µg/L is also proposed. The HBM-GVWorker for U-Cd is similar to the biological limit value (BLV) set by the new amendment of the European Carcinogens and Mutagens Directive in June 2019 (2 µg/g creat for U-Cd).
AIMS: The methodology agreed within the framework of the HBM4EU project is used in this work to derive HBM-GVs for the general population (HBM-GVGenPop) and for workers (HBM-GVWorker) exposed to cadmium (Cd) and its compounds. METHODS: For Cd, a significant number of epidemiological studies with dose-response relationships are available, in particular for kidney effects. These effects are described in terms of a relation between urinary Cd (U-Cd) or blood Cd (B-Cd) levels and low molecular weight proteinuria (LMWP) markers like beta-2-microglobulin (β2M) and retinol-binding protein (RBP). In order to derive HBM-GVs for the general population and workers, an assessment of data from evaluations conducted by national or international organisations was undertaken. In this work, it appeared relevant to select renal effects as the critical effect for the both groups, however, differences between general population (including sensitive people) and workers (considered as an homogenous population of adults who should not be exposed to Cd if they suffer from renal diseases) required the selection of different key studies (i.e. conducted in general population for HBM-GVGenPop and at workplace for HBM-GVWorker). RESULTS AND CONCLUSIONS: For U-Cd, a HBM-GVGenPop of 1 µg/g creatinine (creat) is recommended for adults older than 50 years, based on a robust meta-analysis performed by EFSA (EFSA, 2009a). To take into account the accumulation of Cd in the human body throughout life, threshold or 'alert' values according to age were estimated for U-Cd. At workplace, a HBM-GVWorker of 2 μg/g creat is derived from the study of Chaumont et al., (2011) for U-Cd, and in addition to this recommendation a HBM-GVworker for B-Cd of 5 µg/L is also proposed. The HBM-GVWorker for U-Cd is similar to the biological limit value (BLV) set by the new amendment of the European Carcinogens and Mutagens Directive in June 2019 (2 µg/g creat for U-Cd).
Authors: Sebastian Socianu; Stephanie K Bopp; Eva Govarts; Liese Gilles; Jurgen Buekers; Marike Kolossa-Gehring; Thomas Backhaus; Antonio Franco Journal: Int J Environ Res Public Health Date: 2022-05-18 Impact factor: 4.614
Authors: Jose V Tarazona; Irene Cattaneo; Lars Niemann; Susana Pedraza-Diaz; Maria Carmen González-Caballero; Mercedes de Alba-Gonzalez; Ana Cañas; Noelia Dominguez-Morueco; Marta Esteban-López; Argelia Castaño; Teresa Borges; Andromachi Katsonouri; Konstantinos C Makris; Ilse Ottenbros; Hans Mol; Annelies De Decker; Bert Morrens; Tamar Berman; Zohar Barnett-Itzhaki; Nicole Probst-Hensch; Samuel Fuhrimann; Janja Snoj Tratnik; Milena Horvat; Loic Rambaud; Margaux Riou; Greet Schoeters; Eva Govarts; Marike Kolossa-Gehring; Till Weber; Petra Apel; Sonia Namorado; Tiina Santonen Journal: Toxics Date: 2022-08-04
Authors: James P K Rooney; Bernhard Michalke; Gráinne Geoghegan; Mark Heverin; Stephan Bose-O'Reilly; Orla Hardiman; Stefan Rakete Journal: Environ Sci Pollut Res Int Date: 2022-06-02 Impact factor: 5.190
Authors: Iwona Markiewicz-Górka; Małgorzata Chowaniec; Helena Martynowicz; Anna Wojakowska; Aleksandra Jaremków; Grzegorz Mazur; Piotr Wiland; Krystyna Pawlas; Rafał Poręba; Paweł Gać Journal: Int J Environ Res Public Health Date: 2022-03-06 Impact factor: 3.390